Propensity-matched TriNetX analysis (2022–2024) compared 999 inclisiran-treated ASCVD patients on maximal statins with 999 controls using >30 covariates to reduce confounding. Inclisiran was ...
Please provide your email address to receive an email when new articles are posted on . More than half of patients had intermediate or high risk for developing atherosclerotic CVD within 10 years.
Take a look at the latest weekly editorial and Mallard Fillmore cartoons distributed by the Tribune-Review.
The Newsday app makes it easier to access content without having to log in.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results